

Product Data Sheet

Product Name: Ansornitinib

Cat. No.: GC70992

Chemical Properties

Cas. No. 1448874-96-1

Formula $C_{30}H_{32}N_6O_4$ M.Wt 540.61

Solubility DMSO : 40 mg/mL (73.99 mM);
ultrasonic and warming and heat to
80°C; Hygroscopic DMSO has a
significant impact on the solubility of
product, please use newly opened
DMSO)

Storage -20°C

General tips For obtaining a higher solubility , please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request.


Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

Structure



Background

Ansornitinib is an orally active dual kinase inhibitor that inhibits platelet-derived growth factor receptor (PDGFR) and vascular endothelial growth factor receptor (VEGFR2). Ansornitinib can be used as an antifibrotic agent in lung, liver, kidney, and gastrointestinal fibrotic diseases.

Ansornitinib (compound I) (0.1 nM-10 μ M, 2 h) can significantly inhibit the phosphorylation of PDGFR β in human hepatic stellate cells and KDR phosphorylation in human umbilical vein endothelial cells (HUVEC)^[1].

Ansornitinib (compound I) (0.1-13 μ M, 48 h) can induce a decrease in the expression of many different inflammation-related markers, such as macrophage colony-stimulating factor (M-CSF), soluble interleukin 8, and fibrosis-related markers, such as N-calmodulin, α -SMA, etc., in a dose-dependent manner^[1].

Ansornitinib (compound I) (25 mg/kg, p.o., twice a day, 4 weeks) can reduce fibrosis in TGF β positive female mice^[1].

Ansornitinib (compound I) (5-45 mg/kg, p.o., twice a day, 4 days) can reduce inflammatory bowel disease (IBD) in TNBS-induced IBD/acute colitis male CD-1 mice^[1].

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

References:

[1]. Shakil ASLAM, et al. Reducing fibrosis and treating related diseases, disorders, and conditions.
WO2022006278

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA